XPro(TM) Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
(NASDAQ:INMB), XPro(TM) Treatment Post-TBI Prevents Short- and Long-Term Alzheimer's-like Pathology in transgenic mice Boca Raton, Florida, June 10, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is collaborating with Kirsty Dixon PhD, […]